15.96USD-9.22%Mkt Cap: 12.31B USDP/E: —Last update: 2026-06-01
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate …
Industry Peers
BiotechnologyIndicators:|
Key Statistics
Company
Market Cap12.31B USD
Enterprise Value13.04B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-1.08B USD
Revenue/Share—
Last Price15.96 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees265
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-15.20
PEG—
EV/EBITDA-10.66
EV/Revenue—
P/S—
P/B24.91
EPS (TTM)-1.59
EPS (Forward)-1.15
52W Range
13.8312% of range30.98
52W High30.98 USD
52W Low13.83 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-163.86%
ROA-143.72%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-322.93M USD
CapEx (TTM)657.00K USD
FCF Margin—
FCF Yield0.57%
Net Debt-578.69M USD
Net Debt/EBITDA0.47
Balance Sheet
Debt/Equity0.03
Current Ratio7.41
Quick Ratio7.19
Book Value/Sh0.7040 USD
Cash/Share0.7710 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Target (Mean)28.53 USD
Target Range7.675 USD – 45.06 USD
# Analysts13
Ownership
Shares Out.776.16M
Float134.66M
Insiders82.64%
Institutions15.85%
Short Interest
Short Ratio6.0d
Short % Float22.11%
Short % Out.3.84%
Shares Short29.82M
Short (prev mo.)34.50M
Technical
SMA 5019.00 (-16.0%)
SMA 20018.76 (-14.9%)
Beta-1.25
S&P 52W Chg27.70%
Avg Vol (30d)5.03M
Avg Vol (10d)4.37M
Technical Indicators
RSI (14)47.0
MACD-0.6397
MACD Signal-0.6726
MACD Hist.+0.0329
BB Upper19.18 USD
BB Middle17.40 USD
BB Lower15.63 USD
BB Width20.38%
ATR (14)1.309 USD
Vol Ratio (20d)1.00x